top of page

For Patients
For Healthcare Professionals
- Treating Stage 4 ROS1 (for HCPs)
- ROS1 Clinical Trials
Our Research
Blog
About Us
More

Use tab to navigate through the menu items.

ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

All Posts
Advocacy
Biomarker Testing
Events
Patient-Driven Research
Cancer Progression
Research
Resources
Survivorship
Treatments and Trials
Fundraising
ROS1ders Stories

Search

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 30, 20181 min read

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 13, 20181 min read

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 4, 20181 min read

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Janet Freeman-Daily

Sep 10, 20186 min read

Detection of ROS1 rearrangement in lung cancer remains “complex”

Detection of ROS1 rearrangement in lung cancer remains “complex”

Detection of ROS1 rearrangement in lung cancer remains “complex”

Janet Freeman-Daily

Aug 31, 20181 min read

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 26, 20181 min read

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Janet Freeman-Daily

Jun 14, 20181 min read

Pfizer new lung cancer drug is successful for funding.

Pfizer new lung cancer drug is successful for funding.

Pfizer new lung cancer drug is successful for funding.

Janet Freeman-Daily

May 31, 20181 min read

The Unnecessary Cruelty of Clinical Trials

The Unnecessary Cruelty of Clinical Trials

The Unnecessary Cruelty of Clinical Trials

Apr 6, 20185 min read

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Jan 4, 20174 min read

The ROS1ders, Inc.
1721 Eastern Avenue, Suite 19
Sacramento, CA 95864
+1 (916) 382-8544
info@theros1ders.org

A 501(c)(3) nonprofit corporation
EIN 83-4490547

Disclosures

This website is not intended to, and does not provide, medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

Connect with Our Community

Join Private Facebook Group

Email Webmaster

bottom of page